Alzheimer's & Dementia News and Research

Latest Alzheimer's & Dementia News and Research

BSI: Guidance is key to improve dementia care

Dementia is a critical health concern, but are the current care services able to offer appropriate support? Only a few days ago, the review by the Royal College of Psychiatrists found many dementia patients were not getting the support on nutrition and mental health that they should. The need for improved care is higher than ever.

20 Dec 2010

Proteins that unlock the mystery of over 100 brain diseases

An Anglo-American team of researchers have made a medical breakthrough after identifying a large collection of nerve proteins that are involved in around 130 brain diseases including Alzheimer’s and autism.

20 Dec 2010

Hyperpriming in early stages of Alzheimer's disease explained

The capacity to remember that a zebra has stripes, or that a giraffe is a four-legged mammal, is known as semantic memory. It allows us to assign meaning to words and to recall general knowledge and concepts that we have learned. The deterioration of these capacities is a defining feature of semantic dementia and can also occur in Alzheimer's disease.

20 Dec 2010

Comprehensive guidance for care providers on Dementia Care Mapping process

20 Dec 2010

DiaGenic issues notification of trade among insiders

On 17 December 2010 mandatory notification of trade among insiders of DiaGenic ASA took place.

20 Dec 2010

FVCG invests $175,000 in Celvive for stem cell research in spinal cord injury

Spinal cord injury (SCI) is a devastating neurological condition with limited therapeutic options. In the United States alone, there are more than 250,000 people living with SCI; approximately three million worldwide are affected.

20 Dec 2010

Diagenic, Pfizer enter collaboration to identify biomarkers in early stages of Alzheimer's disease

DiaGenic ASA and Pfizer Inc today signed an agreement for explorative R&D collaboration to identify biomarkers in early stages of Alzheimer's disease (AD) using DiaGenic's patented gene expression technology and its blood samples from ongoing clinical studies.

17 Dec 2010

Alzheimer's Association applauds Congress for passage of NAPA Bill

As the leading care, research and advocacy organization for Alzheimer's disease, the Alzheimer's Association applauds Congress for passage of the National Alzheimer's Project Act (S. 3036, H.R. 4689), a significant step forward in the fight against Alzheimer's disease. The National Alzheimer's Project Act provides an essential framework for the development of a national strategic plan.

17 Dec 2010

Gene variant affects brain function long before brain begins accumulating amyloid: Study

People with a known, high risk for Alzheimer's disease develop abnormal brain function even before the appearance of telltale amyloid plaques that are characteristic of the disease, according to a new study.

17 Dec 2010

Mayo Clinic ACTS project supports African-American dementia caregivers

With a rapidly expanding population of elders, the number of dementia caregivers in Florida is increasing exponentially. According to the Alzheimer's Association, nearly 10 million caregivers provide unpaid care to people with Alzheimer's disease. Finding the best way to support caregivers, especially with fewer state resources available, is one focus of ongoing research at Mayo Clinic in Florida.

17 Dec 2010

Researchers discover new molecular mechanism of Alzheimer's disease through protein interaction

Through a complex analysis of protein interactions, researchers from IRB Barcelona and the Joint Programme IRB-BSC have discovered new molecular mechanisms that may be involved in the development of Alzheimer's disease.

17 Dec 2010

AFFiRiS AG receives 475,000 MJFF grant for Parkinson vaccine development

With a grant of USD 475,000, the Michael J. Fox Foundation is funding preclinical development of a vaccine against Parkinson's disease by AFFiRiS AG. The vaccine, known as PD01, targets the protein alpha-synuclein and might offer for the first time a possibility for a treatment that can slow or stop the progression of Parkinson's disease.

17 Dec 2010

FDA approves Neuralstem's IND to initiate NSI-189 Phase Ia safety trial in major depression

Neuralstem, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to initiate a Phase Ia safety trial to test NSI-189, its first small molecule compound, in major depression. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in depression and other diseases, such as Alzheimer's disease.

17 Dec 2010

Recordati, Nymox sign European licensing agreement for BPH investigational drug, NX-1207

Recordati and Nymox Pharmaceutical Corporation announced today the signing of a European licensing agreement for the development and commercialization of NX-1207, Nymox's Phase III investigational drug currently in clinical development in the U.S. for the treatment of benign prostatic hyperplasia (BPH).

17 Dec 2010

Second brain death exam impacts organ donation rates

Requiring a second exam on a person who is considered brain dead may be unnecessary, according to a study on the impact of a second brain death exam on organ donation rates. The research is published in the December 15, 2010, online issue of Neurology®, the medical journal of the American Academy of Neurology.

16 Dec 2010

Adeona expands and enhances zinc-based product candidate portfolio

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that it has acquired access to clinical data supporting a zinc-based therapy for the prevention of infections in the elderly. This acquisition expands and enhances Adeona's zinc-based product candidate portfolio that already includes its proprietary zinc-based tablets for use in the dietary management of mild to moderate Alzheimer's disease and mild cognitive impairment patients, and age-related macular degeneration.

16 Dec 2010

Alzheimer's Foundation of America praises House, Senate passage of National Alzheimer's Project Act

The Alzheimer's Foundation of America issued this statement today regarding passage of the National Alzheimer's Project Act. The National Alzheimer's Project Act would create the National Alzheimer's Project, which would coordinate government efforts to prevent and treat the disease and create a national strategy for defeating Alzheimer's disease.

16 Dec 2010

Pico-Tesla commences pilot study of Magneceutical Therapy in fibromyalgia patients

Pico-Tesla, The Magneceutical® Company, announced that it has commenced a randomized, double-blind, placebo-controlled pilot study of 30 patients who have fibromyalgia. The pilot study seeks to determine whether the application of magnetic fields generated by Pico-Tesla's patented Resonator™ system can be effective as an adjunctive therapy to oral medications in ameliorating the symptoms of fibromyalgia.

16 Dec 2010

Perirhinal cortex critical for forming unconscious conceptual memories

A small area deep in the brain called the perirhinal cortex is critical for forming unconscious conceptual memories, researchers at the UC Davis Center for Mind and Brain have found.

16 Dec 2010

New study records show dementia residents seek hospice benefit

A new study of nursing home records shows more residents with dementia are seeking a hospice benefit and using it longer. The study also estimates that 40 percent of nursing home residents die with some degree of dementia.

16 Dec 2010